WHO ICTRP trial
A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in…
PER-030-02 · Registro Peruano de Ensayos Clínicos (REPEC) · Not Recruiting
Key facts
| Trial ID | PER-030-02 |
|---|---|
| Public title | A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas. |
| Scientific title | A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas. |
| Primary sponsor | ELI LILLY INTERAMERICA INC., |
| Registry | Registro Peruano de Ensayos Clínicos (REPEC) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | III |
| Countries | Taiwan;Germany;Austria;Belgium;Spain;France;Greece;Netherlands;Italy;Portugal;United Kindgdom;Sweden;Australia;Argentina;Colombia;United States;Venezuela |
| Conditions | -C259 Pancreas, unspecified Pancreas, unspecified;C259;Pancreas, unspecified |
| Interventions | Group name:ALIMTA plus GEMZAR Type of group;1 N° of participants:260 Intervention(s) description:GEMZAR will be administered in doses of 1250 mg/m2 (days 1 and 8) and ALIMTA 500 mg / m2 (day 8). A maximum of 8 cycles will be carried out… |
| Registration date | Mar 27, 2002 |
| Target size | 7 |
| Secondary IDs | NCT00035035 |
| Registry page | ins.gob.pe |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: